Rheumatoid Arthritis — Common Origins, Divergent Mechanisms | NEJM Skip to main content
NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to become a …

The published results of the post-marketing ORAL Surveillance study, which compared the
Janus kinase (JAK) inhibitor tofacitinib with anti-TNF therapy in older patients with …

Objectives To update the Assessment of SpondyloArthritis international Society (ASAS)-
EULAR recommendations for the management of axial spondyloarthritis (axSpA). Methods …

Background Janus kinase (JAK) inhibitors, including baricitinib, block cytokine signaling and
are effective disease-modifying treatments for several autoimmune diseases. Whether …

Atopic dermatitis (AD) is a chronic, inflammatory, pruritic form of dermatosis with
heterogeneous manifestations that can substantially affect patients' quality of life. AD has a …

Summary Background Upadacitinib, a Janus kinase inhibitor, has been shown to be
effective in patients with ankylosing spondylitis. We aimed to assess the efficacy and safety …

Objectives Evaluate risk of major adverse cardiovascular events (MACE) with tofacitinib
versus tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA) with …

Introduction The aim of this work is to evaluate baricitinib safety with respect to venous
thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious …

Protein kinases play a major role in cellular activation processes, including signal
transduction by diverse immunoreceptors. Given their roles in cell growth and death and in …

Objective To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis
(RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD) …